pipette
ESEspañol

Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology

Jing Wang, Peilin Cong, Enduo Feng, Matthias W. G. Zeller, Boyu Zhang, Yifan Lv, Negin Jalali Motlagh, Jenny Linnoila, Han Wang, Cuihua Wang, Zhiming Xu, Ke Gao, Qian Chen, Yu Luo, He Wang, Dalong Ni, Lize Xiong, John W. Chen

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer’s disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 19. Proceedings of the National Academy of Sciences. Peer-reviewed journal.

DOI: 10.1073/pnas.2603280123